DelveInsight's Hemophilia A Market Insights report includes a comprehensive understanding of current treatment practices, hemophilia A emerging drugs, market share of individual therapies, and current ...

Eli Lilly and Company today announced results from the Phase 3 BRUIN CLL-314 clinical trial evaluating Jaypirca (pirtobrutinib), a non-covalent (reversible) Bruton tyrosine kinase (BTK) ...

CSL shares have come under pressure recently. Is this one of those rare moments when a top-tier blue chip becomes a genuine ...

CSL Ltd (ASX:CSL) shares have benefited from strong profit growth. Let’s take a look at what analysts believe could happen ...

Three years after introducing Hemgenix, the first gene therapy for hemophilia B, CSL Behring has released long-term data ...

Australia's CSL is wielding the axe, cutting its workforce by 15% – around 3,000 positions – while announcing plans to spin its vaccines unit into a standalone company. The decision to demerge the CSL ...

Travere Therapeutics and partner CSL Vifor could be weeks away from EU approval of sparsentan for IgA nephropathy, after getting a positive opinion on the drug from the EMA’s human medicines committee ...

An infant botulism outbreak has sickened at least 39 babies across the U.S., underscoring the crucial role of a medication that treats the rare disease.

Here's why brokers are feeling bullish about these three shares this week. The post Brokers name 3 ASX shares to buy today ...

These shares could be top picks for new investors right now. Let's dig deeper into them. The post Here are the 3 Australian stocks I'd tell a new investor to buy asap appeared first on The Motley Fool ...

Plasma physics is the study of a state of matter comprising charged particles. Plasmas are usually created by heating a gas until the electrons become detached from their parent atom or molecule. This ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations for ...